Pharming Group/$PHAR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Ticker
$PHAR
Sector
Primary listing
Employees
404
Headquarters
Website
Pharming Group Metrics
BasicAdvanced
$1B
3,785.00
$0.00
0.16
-
Price and volume
Market cap
$1B
Beta
0.16
52-week high
$21.34
52-week low
$7.50
Average daily volume
29K
Financial strength
Current ratio
2.586
Quick ratio
2.019
Long term debt to equity
38.639
Total debt to equity
41.781
Interest coverage (TTM)
1.78%
Profitability
EBITDA (TTM)
43.458
Gross margin (TTM)
87.90%
Net profit margin (TTM)
0.76%
Operating margin (TTM)
8.57%
Effective tax rate (TTM)
80.25%
Revenue per employee (TTM)
$930,000
Management effectiveness
Return on assets (TTM)
4.48%
Return on equity (TTM)
1.02%
Valuation
Price to earnings (TTM)
3,785
Price to revenue (TTM)
28.689
Price to book
3.17
Price to tangible book (TTM)
6.21
Price to free cash flow (TTM)
200.011
Free cash flow yield (TTM)
0.50%
Free cash flow per share (TTM)
0.076
Growth
Revenue change (TTM)
26.56%
Earnings per share change (TTM)
-122.22%
3-year revenue growth (CAGR)
22.30%
10-year revenue growth (CAGR)
40.32%
3-year earnings per share growth (CAGR)
-40.51%
10-year earnings per share growth (CAGR)
-17.86%
Pharming Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharming Group stock?
Pharming Group (PHAR) has a market cap of $1B as of March 13, 2026.
What is the P/E ratio for Pharming Group stock?
The price to earnings (P/E) ratio for Pharming Group (PHAR) stock is 3785 as of March 13, 2026.
Does Pharming Group stock pay dividends?
No, Pharming Group (PHAR) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Pharming Group dividend payment date?
Pharming Group (PHAR) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group?
Pharming Group (PHAR) has a beta rating of 0.16. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.